The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).
 
Akito Hata
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Taira Ninomaru
No Relationships to Disclose
 
Hideaki Okada
No Relationships to Disclose
 
Yoshihito Kogure
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD (Inst)
 
Masahide Oki
No Relationships to Disclose
 
Nobuyuki Katakami
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Janssen; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Sumitomo Dainippon Pharma; Taiho Pharmaceutical
 
Takashi Kijima
Consulting or Advisory Role - MSD
Research Funding - MSD
 
Toshihide Yokoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb Co. Ltd. (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD K.K (Inst); PAREXEL International Inc. (Inst); Takeda (Inst)
 
Hirotaka Matsumoto
No Relationships to Disclose
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; DaiichiSankyo; Janssen; Merck Serono; MSD; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Sawada
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - Amgen; Anheart Therapeutics; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda; Towa Pharmaceutical
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - A2 Healthcare; Abbvie (Inst); Amgen; Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Corporation; IQvia; Janssen (Inst); Lilly (Inst); Mebix; MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhiko Nakagawa
Honoraria - Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol Myers Squibb Company; Chugai Pharma; CMIC; CMIC Co., Ltd.; Daiichi Sankyo Co., Ltd.; Incyte; Janssen; Japan Clinical Research Operations; Life Technologies; Lilly Japan; Medical Mobile Communications; Merck; MSD K.K; Neo Communication; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kobayashi Pharmaceutical (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Research Support Y.K. (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); Shionogi (Inst); SRL Diagnostics (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)